GALENIC FORMULATIONS OF ORGANIC COMPOUNDS

The present invention relates to a solid unit oral dosage form comprising sacubitril and valsartan in a 1:1 molar ratio, preferably in the form of the so-called angiotensin receptor neprilysin inhibitor (ARNI) LCZ696, which is a complex salt hydrate of sacubitril, valsartan, and sodium ions, appropriate for use in pediatrics or other patients where low and individual dosing is required or who encounter problems with swallowing e.g. as a result of a disease or because of age, to the manufacture of the solid dosage form and to invention embodiments relating to therapy using the dosage form. 本发明涉及适用于儿科或者需要低的个体配量或遇到吞咽困难(例如由于疾病或由于年龄)的其他患者的、包含1:1摩尔比的沙库巴曲和缬沙坦(优选是所谓的血管紧张素受体中性溶酶抑制剂(ARNI)LCZ696的形式，其为沙库巴曲、缬沙坦和钠离子的复合盐水合物)的固体单位口服剂型、所述固体剂型的制备和有关使用所述剂型的疗法的本发明实施方案。